Abciximab Drug info with Brand name and Price

Abciximab Drug info with Brand name and Price

Abciximab

Abciximab Classifications

  • Therapeutic Classification:antiplatelet agents
  • Pharmacologic Classification:glycoprotein iib iiia inhibitors
  • Platelet Glycoprotein  IIb/IIIa Receptor Antagonist
  • SCHEDULE: H
  • Category C
  • STORAGE: Refrigerate at 2-8’C. Do not freeze.
Drug

DOSAGE:

  • Intravenous
  • STABILlSATION IN PATIENTS WLJH UNSTABLE ANGINA: Adult: 250 , mcglkg body weight bolus injection over 1 min followed by 0.125 mcglkg body weight/min infusion, started up to 24 hrs before and 12 hrs after the possible intervention. Max Dose: 10 mcg/min infusion.
  • ADJUNCT FOR THE PREVENTION OF ACUTE ISCHAEMIC COMPLICATIONS IN PERCUTANEOUS TRANSLUMINAL CORONARY PROCEDURES: Adult: 250 mcglkg body weight bolus injection over 1 min followed by 0.125 mcg/kg body weight/min infusion. Max Dose: 10 mcglmin infusion.
Contraindicated of Abciximab in:
  • Hypersensitivity to abciximab or murine (mouse) protein.
  • Active internal bleeding.
  • Recent significant GI or GU bleeding (within 6 wk).
  • History of CVA (within 2 yr) or CVA with neurologic sequelae.
  • History of bleeding disorder.
  • Recent (within 7 days) oral anticoagulant therapy (PT 1.2 times control).
  • Platelet count <100,000 cells/mm³.
  • Recent trauma or major surgery (within 6 wk).
  • Intracranial neoplasm.
  • Aneurysm or AV malformation.
  • Severe uncontrolled hypertension.
  • History of vasculitis.
  • Concurrent use of another parenteral GP IIb/IIIa inhibitor.
  • Recent or concurrent dextran therapy.
  • Cl: Hypersensitivity to any component or to murine proteins; active bleeding; patients at increased risk of haemorrhage, recent (within 6 weeks) GI or genitourinary bleeding of clinical
  • significance; history of cerebrovascular accident (CV A) within 2 yrs or CVA with a significant residual neurological deficit; bleeding diathesis; thrombocytopaenia (10,000 cells/microlitre); clotting abnormalities; administration of oral anticoagulants within 7 days; recent (within 6 weeks) major surgery or trauma; intracranial turner, arteriovenous malformation or aneurysm; severe uncontrolled hypertension; severe renal or hepatic impairment presumed or documented history of vasculitis; use of IV dextran before PTCA, or intent of use during PCTA.
  • SP: Elderly >65 yrs, recent thrombolytic therapy, unsuccessful PTCA. During readministration; use with thrombolytics, anticoagulants and other antiplatelet agents; while obtaining IV route and/or during arterial and venous punctureslintubations; measure platelet count, prothrombin time and APTT to identify preexisting haemostatic abnormalities, before administration; pregnancy and lactation: childn; patients weighing <75 kg.
Use Abciximab Cautiously in:
  • Patients weighing <75 kg or >65 yr (increased risk of bleeding).
  • History of previous GI pathology.
  • Concurrent thrombolytic or heparin therapy.
  • PCI within 12 hr of onset of MI symptoms or PCI procedure lasting >70 min.
  • OB: Lactation: Pedi: Safety not established.
High Alert
  • Used with heparin and aspirin to decrease cardiac ischemic complications before or after percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA).

Unlabeled Uses:

  • In combination with heparin and and/or low-dose alteplase or reteplase to enhance coronary perfusion in patients with acute coronary syndromes (ACS).
Adv. Reactions/Side Effects of Abciximab
  • CNS: abnormal thinking, dizziness , headache.
  • CV: hypotension, atrial fibrillation/flutter , bradycardia, complete AV block, supraventricular tachycardia, vascular disorder, chest pain, peripheral edema.
  • Hemat: bleeding, thrombocytopenia .

Availability

  • Injection: 2 mg/ml in 5-ml vials

Abciximab Brand name and Price —

  • REOPRO Eli Lilly VIAL 2mg/mL 10mg  Price Rs- 19740.00